A phase 1b/2 trial to further advance CLD-101 treatment of newly diagnosed glioma

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jan 2025 According to a Calidi Biotherapeutics media release, company plans to start enrollment in the first quarter 2025.
30 Sep 2024 According to Calidi Biotherapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared Northwestern Universitys Investigational New Drug (IND) application for Calidis CLD-101. Phase 1b/2 trial expected to initiate in the first quarter of 2025 at Northwestern University.
14 May 2024 According to Calidi Biotherapeutics media release, initiation of the Phase 1 trial with Northwestern University anticipated in the third quarter of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com